Celularity Inc

GX Acquisition Corp, trading on Nasdaq under the ticker GXGX and sponsored by GX Clarke & Co., completed its initial public offering in 2018 with a focus on the healthcare and life sciences sector. The blank-check company filed a Form 10-Q on November 13, 2019, reflecting its status as an active SPAC pursuing a business combination target during that period. GX Acquisition Corp ultimately announced a merger with Celularity Inc., a clinical-stage biotechnology company specializing in placental-derived cellular therapeutics, with the transaction closing in 2021 and the combined entity subsequently trading under the ticker CELU. Visit SpacDesk and create a free account to access complete filing histories, sponsor profiles, and deal timelines for GXGX and hundreds of other SPACs.